Princeton Environmental Institute, Princeton, NJ, USA; Public Health Foundation of India, New Delhi, India.
Directorate of Health, Pretoria, South Africa.
Lancet. 2016 Jan 9;387(10014):168-75. doi: 10.1016/S0140-6736(15)00474-2. Epub 2015 Nov 18.
Recent years have seen substantial improvements in life expectancy and access to antimicrobials, especially in low-income and lower-middle-income countries, but increasing pathogen resistance to antimicrobials threatens to roll back this progress. Resistant organisms in health-care and community settings pose a threat to survival rates from serious infections, including neonatal sepsis and health-care-associated infections, and limit the potential health benefits from surgeries, transplants, and cancer treatment. The challenge of simultaneously expanding appropriate access to antimicrobials, while restricting inappropriate access, particularly to expensive, newer generation antimicrobials, is unique in global health and requires new approaches to financing and delivering health care and a one-health perspective on the connections between pathogen transmission in animals and humans. Here, we describe the importance of effective antimicrobials. We assess the disease burden caused by limited access to antimicrobials, attributable to resistance to antimicrobials, and the potential effect of vaccines in restricting the need for antibiotics.
近年来,人们的预期寿命和获得抗菌药物的机会都有了显著提高,尤其是在低收入和中低收入国家,但抗菌药物的病原体耐药性不断增强,有可能使这一进展出现倒退。在卫生保健和社区环境中,耐药生物体对严重感染(包括新生儿败血症和与卫生保健相关的感染)的生存率构成威胁,并限制了手术、移植和癌症治疗的潜在健康获益。在扩大抗菌药物合理使用机会的同时,限制不合理使用机会(尤其是限制昂贵的新一代抗菌药物的不合理使用)的挑战在全球卫生领域是独特的,这需要为医疗保健提供资金并找到新的方法,同时需要从动物和人类之间病原体传播的“同一健康”视角来考虑这一问题。在这里,我们描述了有效抗菌药物的重要性。我们评估了因抗菌药物耐药性导致的抗菌药物获取受限所带来的疾病负担,以及疫苗在限制对抗生素的需求方面的潜在作用。